Finance
COVID-19 variant Eris in India: Eris, the new COVID-19 version, has become a source of concern. According to media sources, the variant’s incidence is expanding globally.
According to the Indian Express, there has only been one reported instance of the EG.5.1 variety, which was discovered in Pune in May 2023. According to experts, no “clustering” or rise in cases has been reported in India. The Indian SARS-CoV-2 Genomics Consortium (Insacog) reports that no anomalous pattern associated with the COVID-19 mutation has been detected in the country.
Eris has been found in 51 countries, including China, the United States, the Republic of Korea, Japan, Canada, Australia, Singapore, the United Kingdom, France, Portugal, and Spain, according to the World Health Organization (WHO).
“The emergence of the ERIS (EG.5.1) COVID variant, a descendant of Omicron, has led to a surge in infections globally, particularly in Asia and within India. In a recent survey, significant proportions of households in Karnataka, Delhi, and Maharashtra reported viral fever or COVID-like symptoms. As doctors, our focus must be on adapting strategies, enhancing vaccination efforts, early reporting and maintaining vigilant healthcare systems. Booster shots and continued preventive measures are crucial to managing this new challenge. Be alert to symptoms like runny nose, cough, fever, and fatigue, and seek medical advice as needed,” Dr Dipu TS, Associate Professor, Division of Infectious Diseases, Amrita Hospital, Kochi told Financial Express.com.
The WHO recently designated “Eris” as a “variant of interest.” This means that it should be monitored more closely than others due to mutations that could make it more contagious or severe.
According to the World Health Organization, it does not appear to pose a greater hazard to public health than other variants at this time, and there is “no evidence of an increase in disease severity directly associated with EG.5”
“EG5.1, or ERIS variant, classified by the WHO presently as a “variant under monitoring”, is a sub-variant of the Omicron strain. It has mutations in the spike (or binding) protein, which are hypothesized to improve its ability to bind, and therefore propagate better, resulting in increased transmissibility. This increased transmissibility is causing an increasing number of cases in the UK, and the variant appears to be gradually replacing the existing variants of XBB circulating in the community,” Dr. Lancelot Mark Pinto, Consultant Pulmonologist and Epidemiologist, P.D. Hinduja Hospital & MRC, Mahim told.
According to Dr. Pinto, there are no reasons at present to be worried about the new variant.
“However, it is important to realize that lower respiratory tract infections (such as influenza) are a leading cause of hospitalization and death all over the world, and they should not be taken lightly, especially among those who are vulnerable. Protecting one’s respiratory health should always be a priority irrespective of which variants or which viruses seem to be circulating in the community. Constant surveillance will enable us to know whether added precautions are needed, and at present, this does not seem to be the case for the new variant,” he told.
Source:FE
